Boston Scientific Corporation $BSX Shares Purchased by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 7.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 362,842 shares of the medical equipment provider’s stock after acquiring an additional 25,797 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Boston Scientific were worth $38,973,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of BSX. Sound Income Strategies LLC boosted its stake in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the period. 1248 Management LLC bought a new stake in shares of Boston Scientific during the first quarter valued at approximately $26,000. Y.D. More Investments Ltd bought a new stake in shares of Boston Scientific during the first quarter valued at approximately $27,000. Princeton Global Asset Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth approximately $32,000. Finally, Migdal Insurance & Financial Holdings Ltd. grew its holdings in Boston Scientific by 72.9% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 344 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 145 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $102.73 on Friday. Boston Scientific Corporation has a 52 week low of $85.98 and a 52 week high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The stock has a market cap of $152.30 billion, a PE ratio of 54.94, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58. The company’s 50-day moving average price is $99.72 and its two-hundred day moving average price is $102.56.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The company had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the previous year, the company posted $0.63 EPS. The business’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,561,336.74. This trade represents a 21.90% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 175,782 shares of company stock worth $17,742,314. 0.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have weighed in on BSX shares. Jefferies Financial Group reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Barclays lifted their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Robert W. Baird increased their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Truist Financial boosted their price target on shares of Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $125.00 price objective on shares of Boston Scientific in a report on Monday, September 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Buy” and a consensus target price of $123.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.